Last reviewed · How we verify

NCT03647085: CAFE

Data Collection Atrial Fibrillation Exploratory Study

Terminated Last updated 9 June 2022
What this trial tests

trial testing Wearable cardiac monitor in Atrial Fibrillation in 27 participants. Terminated before completion.

Timeline
29 August 2018
Primary endpoint
10 January 2019
10 January 2019

Quick facts

Lead sponsorBoston Scientific Corporation
StatusTerminated
Study typeOBSERVATIONAL
Enrollment27
Start date29 August 2018
Primary completion10 January 2019
Estimated completion10 January 2019
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Boston Scientific Corporation — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation or Atrial Flutter. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To characterize the impact of Atrial fibrillation (AFib) and Atrial Flutter (AFl) on signals measured using a wearable cardiac monitor prototype device. To evaluate the relationship of AFib/AFl symptom severity with various physiologic signals measured from the wearable cardiac monitor prototype device.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Wearable cardiac monitor

Trials testing the same drug.

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Boston Scientific Corporation trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03647085.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing